1Y Close · As of Aug 26, 2026
BIODYNE operates in the Medical, Precision & Optical sector.
Legal name: BIODYNE CO., LTD.
In fiscal year 2025, BIODYNE (314930) reported revenue of 7.0 billion KRW, up 33.3% from 5.3 billion KRW a year earlier.
Operating profit was 652 million KRW and net income was 852 million KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 221.1 billion KRW, with a P/B of 5.02.
These figures can be verified in the DART filing (receipt no. 20260313000802).
Recent Filings
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Lending Decision (Voluntary Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Large Shareholding Report (General) |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-03 | Lending Decision (Voluntary Disclosure) |